New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
11:16 EDTDLLR, MNKD, CYTK, APOL, GALTOptions with decreasing implied volatility: MNKD GALT CYTK DLLR APOL
News For MNKD;GALT;CYTK;DLLR;APOL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 25, 2015
16:21 EDTAPOLOn The Fly: Closing Wrap
Stocks opened in quiet fashion and trading remained that way throughout most of the morning. The averages broke to the downside a bit before noon and once the sellers gained control the move became broad based. Each of the major equity averages dropped by about 1.5% or more, with the Nasdaq losing more than 2% of its value during the session. ECONOMIC EVENTS: In the U.S., durable goods orders dropped 1.4% in February, falling well below the consensus call for a 0.2% rise for the month. Transportation orders fell 3.5%, with orders excluding transportation down 0.4% against expectations of a 0.2% positive movement. In Europe, Germany's Ifo institute business climate index rose to 107.9 from 106.8 in March, topping expectations. COMPANY NEWS: Kraft Foods (KRFT) surged $21.84, or 35.62%, to $83.17 after announcing it has entered a definitive merger agreement with H.J. Heinz to create the Kraft Heinz Company. Under the terms of the deal, Heinz-owners Berkshire Hathaway (BRK.A) and 3G Capital will fund a special $10B cash dividend of $16.50 per share for Kraft shareholders. The new company, which will be publicly traded and 49% owned by current Kraft shareholders 51% owned by current Heinz shareholders, will become the third-largest food and beverage company in North America and fifth largest food and beverage company in the world. MAJOR MOVERS: Among the notable gainers was Kofax (KFX), which jumped $3.45, or 46%, to $10.95 after agreeing be acquired by Lexmark (LXK) for $11.00 per share in cash for a total enterprise value of approximately $1B, net of cash acquired. Lexmark, which stated the deal will "nearly double" its enterprise software business to roughly $700M, also gained $2.48, or 6.08%, to $43.27. Among the noteworthy losers was Apollo Education Group (APOL), which fell $7.95, or 28.4%, to $20.04 after reporting Q2 earnings and University of Phoenix enrollment information. Also lower were shares of Nationstar Mortgage (NSM), which declined $5.15, or 16.54%, to $25.99 after its 17.5M share spot secondary offering of stock priced at $28.95 per share. INDEXES: The Dow declined 292.60, or 1.62%, to 17,718.54, the Nasdaq fell 118.21, or 2.37%, to 4,876.52, and the S&P 500 dropped 30.45, or 1.46%, to 2,061.05.
12:52 EDTAPOLOn The Fly: Midday Wrap
Subscribe for More Information
10:03 EDTAPOLHigh option volume stocks
High option volume stocks: NVO SXC SONC EXH KRFT WLB ETR LXK APOL EWH
09:57 EDTAPOLApollo Education tumbles after earnings and guidance, levels to watch
Subscribe for More Information
09:24 EDTAPOLOn The Fly: Pre-market Movers
Subscribe for More Information
07:38 EDTCYTKCytokinetics publishes results from Tirasemtiv Phase II trial
Subscribe for More Information
07:38 EDTAPOLApollo Education reports University of Phoenix revenue $487.77M
Subscribe for More Information
07:35 EDTAPOLApollo Education sees Q3 revenue $690M-$705M, consensus $740.86M
Sees Q3 operating income $85M-$95M, excluding special items.
07:34 EDTAPOLApollo Education sees FY15 revenue $2.63B-$2.68B, consensus $2.73B
Subscribe for More Information
07:32 EDTAPOLApollo Education reports Q2 EPS ex-items (10c), consensus (16c)
Subscribe for More Information
06:20 EDTAPOLUniversity of Phoenix could post stronger Q2 recruitment, WSJ says
Apollo Education's University of Phoenix may post improved Q2 results Wednesday, says the Wall Street Journal, citing a Deutsche Bank estimate of recruiting. The Journal also notes that improved online software may have improved student retention rates for the quarter, though it cautions that a "rebirth" for the organization is not likely. Reference Link
March 24, 2015
15:32 EDTAPOLApollo Education April volatility elevated into Q4 and outlook
Subscribe for More Information
15:28 EDTAPOLNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Paychex (PAYX), consensus 46c... Leidos (LDOS), consensus 48c... Apollo Education (APOL), consensus (16c)... Lindsay (LNN), consensus $1.13... Francesca's (FRAN), consensus 20c... Yingli Green Energy (YGE), consensus (13c).
05:46 EDTMNKDStocks with implied volatility movement; AMZN MNKD
Subscribe for More Information
March 20, 2015
16:00 EDTMNKDOptions Update; March 20, 2015
Subscribe for More Information
March 18, 2015
17:14 EDTGALTGalectin submitted request for SPA with clinical protocol for GR-MD-02 trial
"I am pleased with our many accomplishments during 2014 as we continue to advance programs with GR-MD-02 for the treatment of nonalcoholic steatohepatitis, NASH, with advanced fibrosis. We completed a successful Phase 1 clinical trial and announced final data in January 2015 that were supportive of our plans to begin a Phase 2 program with GR-MD-02 in advanced fatty liver disease, or NASH with fibrosis and cirrhosis," said Peter G. Traber, M.D., president, CEO and chief medical officer of Galectin Therapeutics. "As announced last month, we submitted the Phase 2 clinical trial protocol to the U.S. Food and Drug Administration, FDA, to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis, the primary endpoint being to determine the change in the hepatic venous pressure gradient, HVPG, as compared with placebo. The FDA has indicated that HVPG may serve as a surrogate primary endpoint for NASH cirrhosis. We submitted a request for a Special Protocol Assessment with the clinical protocol for this trial. Additionally, we are planning to conduct a separate, shorter Phase 2 trial in NASH patients with advanced fibrosis. We expect to begin enrolling patients in both trials during the second quarter of 2015."
17:08 EDTGALTGalectin Therapeutics reports FY14 EPS (78c), consensus (77c)
As of December 31, the company had $29.1M of non-restricted cash and cash equivalents available to fund future operations. In January and February of 2015, the company received $4.1M in net proceeds from the issuance of common shares through its At-the-Market stock issuance program. The company believes that cash on hand of $29.7M as of March 13, is sufficient to fund its operations and research and development activities through September 30, 2016.
09:32 EDTMNKDMannKind faces cash shortfall if $100M debt not settled, TheStreet says
Subscribe for More Information
March 16, 2015
17:13 EDTGALTGalectin Therapeutics files form to delay 10-K
Galectin Therapeutics is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the period ended December 31. Because the company was previously a smaller reporting company, this is the first time the company must obtain an audit of its internal control over financial reporting. As a result, additional time is needed for the company to provide its independent auditors with information necessary to complete the audit of the company’s internal control over financial reporting. The company anticipates that its Form 10-K will be filed within the prescribed extension period in accordance with Rule 12b-25(b).
11:20 EDTMNKDStocks with call strike movement; MNKD BBRY
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use